The DDR H1 Landscape Review 2024
A complete review of the entire DDR drug, trial and commercial landscape from H1, along with insights into the endometrial cancer landscape and the future of the field.
About the report
The analysis includes:
-
- The Drug and Trial Landscape – An analysis of the 650+ DDR-related drugs and 1,650+ trials hosted on Beacon DDR
- Commercial Landscapes – An overview of the commercial landscape, looking into deals and companies analysed by target, deal type and geographical location
- The Endometrial Cancer Landscape – Insight into the endometrial cancer landscape off the back of the first DDR approval for endometrial cancer treatment. Looking at how PARP inhibitors are being investigated with particular focus on their combinations with immune checkpoint modulators.
- The Future of DDR – A look into emerging combination therapies, particularly DDR inhibitors (DDRi’s) and antibody-drug conjugates (ADC’s), along with the drugs to keep an eye on in 2024
You may also be interested in...
DDRi and ADC Combination Therapies Infographic
The 2024 DDR H1 Landscape Review
Investment Trends in Early-Stage Biopharma: A Beacon Data Perspective
Find out more
Beacon is the essential decision-support tool for developers of complex therapeutics. Our market-defining, proprietary ontologies, combined with the most accurate and comprehensive life sciences data, provide our customers with unparalleled visibility of the drug and trial landscape.
With Beacon, you can make drug development decisions with confidence. This is why 23 of the world’s top 25 drug developers trust us.
Speak with our team
Our dedicated account and research teams can help you with questions by showing you how this insight and data is collated on Beacon.
